Basiliximab

A recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. Basiliximab selectively binds to and blocks IL-2R alpha, expressed on the surface of activated T-lymphocytes, thereby preventing interleukin-2 binding and inhibiting the interleukin-2-mediated activation of lymphocytes.

Medicine

Pharmacological class:

Pregnancy category:

Marketed formulations:

Active moieties:

Active moiety of formulation:

Active moiety of drug:

top ↑

Facts from the Community

From the BioVenturist base

Technology involved:

View entire collection »

Developed by:

Brand Names:

  • Simulect

Stage of development:

Target/Biomolecule of Interest:

Indication or disease:

Disease Phase of development

Approval Date:

  • 1998
top ↑

We can also tell you Basiliximab is a…

If you know more about Basiliximab, you can add more facts here »

These people have edited this topic:

Edit this topic
Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

Freebase Logo
What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Freebase Attribution

Freebase data is free for use under the CC-BY license.

Learn more about Freebase licensing and attribution »